Oracea, to treat inflammatory lesions on skin due to rosacea/skin conditions

Institution:

Stony Brook University School of Medicine

Researchers:

Lorne Golub, DMD, MSc, of the Department of Oral Biology and Pathology at Stony Brook Medicine

Impact:

Rosacea affects an estimated 16 million Americans. Dr. Golub was the principal investigator of the research leading to the development of Oracea. The drug delivers a dose of doxycycline that is not strong enough to kill bacteria, but that will reduce lesions and inflammation.

Timeline:

FDA approval in 2006